Key clinical point: Early treatment with postoperative biological therapy decreased endoscopic recurrence rates and improved long-term outcomes in patients who underwent Crohn’s disease (CD)-related surgery.
Major finding: The rate of endoscopic recurrence was higher in patients not treated vs. treated with early postoperative biological therapy (80.8% vs. 45.2%; P < .000024), with the risk of experiencing hospitalization or surgery at 5 years being 23.3% higher ( P = .02221) and the rate of medical therapy escalation being significantly higher (66.0% vs. 14.0%; P < .00001) in the no-treatment vs. treatment group.
Study details: Findings are from a retrospective cohort study including 141 patients with CD who underwent surgery and colonoscopy at 6-12 months postoperatively.
Disclosures: This study did not receive any funding. Some authors declared receiving consulting fees, lecture fees, speaker’s fees, grants, or serving as advisory board members for various sources.
Source: D'Amico F et al. Early biological therapy in operated Crohn’s disease patients is associated with a lower rate of endoscopic recurrence and improved long-term outcomes: A single-center experience. Inflamm Bowel Dis. 2022 (May 28). Doi: 10.1093/ibd/izac110